ArticleESMO real world data and digital oncology2026

Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE).

H Abdallah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.